Rachel Schwartz
Vice President Of Business Development and Commercial at Volastra Therapeutics - New York, NY, US
Rachel Schwartz's Colleagues at Volastra Therapeutics
Rachel Schwartz's Contact Details
N/A
Volastra Therapeutics
Rachel Schwartz's Company Details
Volastra Therapeutics, Inc., is developing novel therapies to treat cancer. Launched from the laboratory of Dr. Lewis Cantley, along with Drs. Olivier Elemento and Samuel Bakhoum, Volastra has identified the mechanisms by which CIN drives the formation and proliferation of solid tumors. Following initial evidence that a patient's CIN status is prognostic and that CIN alters cellular and immune response mechanisms and leads to worse overall survival in mouse models, the company is discovering mechanisms and pathways by which CIN modulates disease to develop novel therapeutics.